Strong EBIT growth (+70%) and significant increase in earnings per share (+57%)
|
EQS-News: M1 Kliniken AG
/ Key word(s): Preliminary Results/Quarter Results
M1 Kliniken AG publishes preliminary figures for the 2024 financial year: Strong EBIT growth (+70%) and significant increase in earnings per share (+57%) Berlin, April 29, 2025 - M1 Kliniken AG (ISIN: DE000A0STSQ8) has published its preliminary IFRS consolidated figures for the 2024 financial year. The Group once again recorded strong growth in its operating business and benefited from the continued high demand for beauty treatments and the consistent implementation of its efficiency strategy.
Key figures at a glance:
Five new clinics were opened in Germany and abroad in the past financial year. As a result, the M1 Group operates a total of 63 clinics in ten countries as at 31/12/2024 and is further expanding its market leadership in Europe and Australia in the field of beauty treatments.
Development of the segments: The Beauty segment continues to be the Group’s main growth driver:
The Trading segment also developed positively:
The financial result declined to EUR -0.5 million (previous year: EUR 0.8 million) due to higher interest rates. Earnings before taxes (EBT) increased by 53% to EUR 26.3 million in the 2024 financial year (previous year: EUR 16.4 million). Equity amounted to EUR 134.2 million as at 31/12/2024 (previous year: EUR 143.2 million). Due to the reduction in liabilities, the equity ratio rose from 67% to 71%, confirming the company's solid financial stability.
Outlook: For the 2025 financial year, M1 Kliniken AG plans to systematically continue its profitable growth through the further expansion of national and international clinics. By 2029, annual revenue of EUR 200 to 300 million with an EBIT margin of at least 20% is targeted within the Beauty segment. Current geopolitical developments do not affect the business activities of the M1 Group, as there are no operating locations in relevant regions and no supply or service relationships are affected.
About M1 Kliniken AG: M1 Kliniken AG is the leading fully integrated provider of aesthetic medical healthcare services in Europe and Australia. The Group offers products and services of the highest quality standards in the aesthetic and surgical fields. M1 currently offers beauty treatments at 63 clinics under the "M1 Med Beauty" brand. The M1 Schlossklinik for Plastic and Aesthetic Surgery in Berlin is one of the largest and most modern facilities of its kind in Europe, with six operating theaters and 35 beds. M1 has been driving forward its internationalization since the end of 2018 and is currently represented in ten countries. Contact: M1 Kliniken AG Grünauer Straße 5 12557 Berlin T: +49 (0)30 347 47 44 14 M: ir@m1-kliniken.de
29.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | M1 Kliniken AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | +49 (0)30 347 47 44 14 |
| Fax: | +49 (0)30 347 47 44 17 |
| E-mail: | ir@m1-kliniken.de |
| Internet: | https://www.m1-kliniken.de |
| ISIN: | DE000A0STSQ8 |
| WKN: | A0STSQ |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2125860 |
| End of News | EQS News Service |
|
|
2125860 29.04.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.